Cel Sci Corporation (CVM)

[sab63090]

[b]Pathway Cos[/b] (see Peloton Pharm acquistion this morn) saw this comment from someone well versed in the science:

The science suggests that the best way to target solid tumors is to go after the mutated pathways that drive their growth. Right now, not even T cell therapies can hold up to the data we see from well planned pathway drugs. Its about understanding the genetics, mutations and going after what drives uncontrolled growth.